Johns Hopkins KRAS Vaccine Shows Promise in Preventing Pancreatic Cancer

Pancreatic cancer remains one of the deadliest cancers; this preventive approach could eliminate suffering for high-risk populations.

For generations, pancreatic cancer has been a diagnosis that arrived too late to change much — a disease defined by its silence and its lethality. Researchers at Johns Hopkins have now begun testing whether that silence can be broken before it begins, developing a vaccine that trains the immune system to recognize and destroy cells carrying the KRAS mutation, present in nearly nine of ten pancreatic cancers, before they ever become malignant. Focused on high-risk individuals, the trial has demonstrated a durable immune response — the body learning a vigilance it does not forget. If larger stud

Johns Hopkins KRAS Vaccine Shows Promise in Preventing Pancreatic Cancer

Cobertura Relacionada

Receba o Register no seu e-mail